Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Decreased pulse rate01:14

Decreased pulse rate

639
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
639
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

186
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
186
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.2K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.0K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.0K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

165
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
165
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

128
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nano-vectors for CRISPR/Cas9-Mediated Genome Editing.

Nano today·2026
Same author

Adverse events associated with endoscopic retrograde cholangiopancreatography (ERCP) and ERCP-related procedures.

Gastrointestinal endoscopy·2026
Same author

American Society for Gastrointestinal Endoscopy guideline on endoscopic management of benign and malignant colonic strictures.

Gastrointestinal endoscopy·2026
Same author

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Blood·2025
Same author

Hand hygiene on gloved hands: is glove integrity compromised by repeated disinfections?

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025
Same author

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Blood advances·2025

Related Experiment Video

Updated: Oct 21, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K

Remdesivir-associated bradycardia.

Patrick R Ching1, Calvin Lee2

  • 1Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA patrickrching@gmail.com.

BMJ Case Reports
|September 4, 2021
PubMed
Summary
This summary is machine-generated.

Remdesivir treatment for COVID-19 may cause bradycardia, a slow heart rate. Healthcare providers should monitor patients

Keywords:
COVID-19cardiovascular medicinedrugs and medicinesinfectious diseases

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.9K
Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device
06:51

Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device

Published on: July 29, 2016

8.0K

Related Experiment Videos

Last Updated: Oct 21, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.9K
Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device
06:51

Development of an Algorithm to Perform a Comprehensive Study of Autonomic Dysreflexia in Animals with High Spinal Cord Injury Using a Telemetry Device

Published on: July 29, 2016

8.0K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Remdesivir is an antiviral medication used for hospitalized COVID-19 patients.
  • Limited data exists on the cardiovascular safety profile of Remdesivir.
  • COVID-19 itself can affect cardiovascular function.

Observation:

  • A case study involving a 37-year-old male patient with COVID-19 is presented.
  • The patient developed bradycardia (slow heart rate) after administration of Remdesivir.
  • No other potential causes for bradycardia were immediately apparent.

Findings:

  • Remdesivir administration was temporally associated with the onset of bradycardia in this patient.
  • This case highlights a potential cardiovascular adverse effect of Remdesivir.
  • Underlying cardiovascular conditions or concurrent medications may increase risk.

Implications:

  • Baseline electrocardiogram (ECG) is recommended before initiating Remdesivir.
  • Continuous cardiac monitoring during Remdesivir treatment is advised.
  • Particular caution is warranted for patients with pre-existing cardiovascular disease, the elderly, and those on beta-blocker therapy.